Management for persistent HPV infection and cervical lesions among women infected with HIV: a retrospective observational cohort study.


Journal

Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645

Informations de publication

Date de publication:
06 Jun 2024
Historique:
received: 17 04 2024
accepted: 03 06 2024
medline: 7 6 2024
pubmed: 7 6 2024
entrez: 6 6 2024
Statut: epublish

Résumé

Early diagnosis and treatment of HPV persistent infection and cervical intraepithelial neoplasia, which have yet to be thoroughly characterized in Guangxi, Southwestern China, are the key preventative measures for the development of cervical cancer in women, particularly in HIV-infected women. A retrospective study of 181 patients with HPV infection or cervical intraepithelial neoplasia who received surgical excision of lesions and were prospectively enrolled at the Fourth People's Hospital of Nanning between January 2018 and February 2023 was performed. HPV-infected patients were divided into two subgroups: HIV-infected and HIV/HPV-coinfected patients and compare differences between these groups. HPV16, 18, 52, and 58 were the most prevalent HPV genotypes. High-risk HPV was significantly co-infected with multiple genotypes (P = 0.0332). HIV-infected women were predisposed to HPV infection (P < 0.0001), and the development of cervical cancer at a young age (P = 0.0336) compared to HIV-uninfected women and the loop electrosurgical excision procedure (P = 0.0480) is preferred for the treatment. HIV infection may increase HPV prevalence and lead to cervical cancer development at a young age. The loop electrosurgical excision procedure is an efficient evaluation and treatment strategy for HIV-infected women suffering from cervical intraepithelial neoplasia.

Sections du résumé

BACKGROUND BACKGROUND
Early diagnosis and treatment of HPV persistent infection and cervical intraepithelial neoplasia, which have yet to be thoroughly characterized in Guangxi, Southwestern China, are the key preventative measures for the development of cervical cancer in women, particularly in HIV-infected women.
METHODS METHODS
A retrospective study of 181 patients with HPV infection or cervical intraepithelial neoplasia who received surgical excision of lesions and were prospectively enrolled at the Fourth People's Hospital of Nanning between January 2018 and February 2023 was performed. HPV-infected patients were divided into two subgroups: HIV-infected and HIV/HPV-coinfected patients and compare differences between these groups.
RESULTS RESULTS
HPV16, 18, 52, and 58 were the most prevalent HPV genotypes. High-risk HPV was significantly co-infected with multiple genotypes (P = 0.0332). HIV-infected women were predisposed to HPV infection (P < 0.0001), and the development of cervical cancer at a young age (P = 0.0336) compared to HIV-uninfected women and the loop electrosurgical excision procedure (P = 0.0480) is preferred for the treatment.
CONCLUSIONS CONCLUSIONS
HIV infection may increase HPV prevalence and lead to cervical cancer development at a young age. The loop electrosurgical excision procedure is an efficient evaluation and treatment strategy for HIV-infected women suffering from cervical intraepithelial neoplasia.

Identifiants

pubmed: 38844960
doi: 10.1186/s12985-024-02405-y
pii: 10.1186/s12985-024-02405-y
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

133

Informations de copyright

© 2024. The Author(s).

Références

Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R et al. Cancer incidence in five continents volume IX. Int Agency Res Cancer. 2021. https://doi.org/https://ci5.iarc.who.int/ .
Sung HFJS. Global cancer statistics 2020: global cancer estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca: A Cancer Journal for Clinicians. 2021; 71:209 – 49. https://doi.org/10.3322/caac.21660 .
Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Sci (American Association Advancement Science). 1990;248(4951):76–9. https://doi.org/10.1126/science.2157286 .
doi: 10.1126/science.2157286
Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of ~ 53. Cell. 1990;63:1129–36. https://doi.org/10.1016/0092-8674(90)90409-8 .
doi: 10.1016/0092-8674(90)90409-8 pubmed: 2175676
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of ~ 53. Cell. 1993;75:495–505. https://doi.org/10.1016/0092-8674(93)90384-3 .
doi: 10.1016/0092-8674(93)90384-3 pubmed: 8221889
Waggoner SE. Cervical cancer. Lancet. 2003;361:2217–25. https://doi.org/10.1016/S0140-6736(03)13778-6 .
doi: 10.1016/S0140-6736(03)13778-6 pubmed: 12842378
Münger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 1989;8(13):4099–105. https://doi.org/10.1002/j.1460-2075.1989.tb08594.x .
doi: 10.1002/j.1460-2075.1989.tb08594.x pubmed: 2556261 pmcid: 401588
Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC et al. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between the transcription factor E2F and the retinoblastoma gene product. Proceedings of the National Academy of Sciences. 1992; 89:4549-53. https://doi.org/10.1073/pnas.89.10.4549 .
Yang X, Li Y, Tang Y, Li Z, Wang S, Luo X, et al. Cervical HPV infection in Guangzhou, China: an epidemiological study of 198,111 women from 2015 to 2021. Emerg Microbes Infect. 2023;12(1):e2176009. https://doi.org/10.1080/22221751.2023.2176009 .
doi: 10.1080/22221751.2023.2176009 pubmed: 36744409 pmcid: 9936994
Soto D, Song C, Mclaughlin-Drubin ME. Epigenetic alterations in human papillomavirus-associated cancers. Viruses. 2017;9(9). https://doi.org/10.3390/v9090248 .
Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE, et al. A review of human carcinogens—part B: biological agents. Lancet Oncol. 2009;10(4):321–2. https://doi.org/10.1016/S1470-2045(09)70096-8 .
doi: 10.1016/S1470-2045(09)70096-8 pubmed: 19350698
Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30. https://doi.org/10.1016/j.vaccine.2012.06.083 . F55-70.
Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27. https://doi.org/10.1056/NEJMoa021641 .
doi: 10.1056/NEJMoa021641 pubmed: 12571259
Paul A, Cohen AJAO. Cervical cancer. Lancet. 2019;393:169–82. https://doi.org/10.1016/S0140-6736(18)32470-X .
doi: 10.1016/S0140-6736(18)32470-X
Clark E, Chen L, Dong Y, Raychaudhury S, White D, Kramer JR, et al. Veteran women living with human immunodeficiency virus have increased risk of human papillomavirus (HPV)-associated genital tract cancers. Clin Infect Dis. 2021;72(9):e359–66. https://doi.org/10.1093/cid/ciaa1162 .
doi: 10.1093/cid/ciaa1162 pubmed: 32785700
Cox JT. Management of cervical intraepithelial neoplasia. Lancet. 1999;353:857–9. https://doi.org/10.1016/S0140-6736(98)00392-4 .
doi: 10.1016/S0140-6736(98)00392-4 pubmed: 10093973
Basu P, Taghavi K, Hu S, Mogri S, Joshi S. Management of cervical premalignant lesions. Curr Probl Cancer. 2018;42(2):129–. https://doi.org/10.1016/j.currproblcancer.2018.01.010 . https://doi.org/https://doi.org/ .  36.
doi: 10.1016/j.currproblcancer.2018.01.010 pubmed: 29428790
Prendiville W, Davies R, Berry PJ. A low voltage diathermy loop for taking cervical biopsies: a qualitative comparison with punch biopsy forceps. Br J Obstet Gynaecol. 1986;93(7):773–6. https://doi.org/10.1111/j.1471-0528.1986.tb08066.x .
doi: 10.1111/j.1471-0528.1986.tb08066.x pubmed: 3730349
Olorunfemi G, Ndlovu N, Masukume G, Chikandiwa A, Pisa PT, Singh E. Temporal trends in the epidemiology of cervical cancer in South Africa (1994–2012). Int J Cancer. 2018;143(9):2238–49. https://doi.org/10.1002/ijc.31610 .
doi: 10.1002/ijc.31610 pubmed: 29786136 pmcid: 6195436
Rahel Ghebre SGMJ. Cervical cancer control in HIV-infected women: past, present and future. Gynecol Oncol Rep. 2017;21:101–8. https://doi.org/10.1016/j.gore.2017.07.009 .
doi: 10.1016/j.gore.2017.07.009 pubmed: 28819634 pmcid: 5548335
Han MR, Shin S, Park HC, Kim MS, Lee SH, Jung SH, et al. Mutational signatures and chromosome alteration profiles of squamous cell carcinomas of the vulva. Exp Mol Med. 2018;50(2):e442. https://doi.org/10.1038/emm.2017.265 .
doi: 10.1038/emm.2017.265 pubmed: 29422544 pmcid: 5903820
Mitchell Maiman RGFE. Human lmmunodeficiency virus infection and cervical neoplasia. Gynecol Oncol. 1990;38(3):377–82. https://doi.org/10.1016/0090-8258(90)90077-X .
doi: 10.1016/0090-8258(90)90077-X
Martínez-Gómez X, Curran A, Campins M, Alemany L, Rodrigo-Pendás JÁ, Borruel N, et al. Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016. Euro Surveillance: Bulletin Européen. Sur Les Maladies Transmissibles. 2019;24(7). https://doi.org/10.2807/1560-7917.ES.2019.24.7.1700857 .
Crowley-Nowick PA, Ellenberg JH, Vermund SH, Douglas SD, Holland CA, Moscicki AB. Cytokine profile in genital tract secretions from female adolescents: impact of human immunodeficiency virus, human papillomavirus, and other sexually transmitted pathogens. J Infect Dis. 2000;181(3):939–45. https://doi.org/10.1086/315311 .
doi: 10.1086/315311 pubmed: 10720516
Castle PE. Cervical cancer prevention and control in women living with human immunodeficiency virus. Cancer J Clin. 2021;71(6):505–26. https://doi.org/10.3322/caac.21696 .
doi: 10.3322/caac.21696
Firnhaber C, Van Le H, Pettifor A, Schulze D, Michelow P, Sanne IM, et al. Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control. 2010;21(3):433–43. https://doi.org/10.1007/s10552-009-9475-z .
doi: 10.1007/s10552-009-9475-z pubmed: 19949850
Wu Z, Chen, Junfang, Scott S, Robbins, McGoogan, Jennifer M. History of the HIV epidemic in China. Curr HIV/AIDS Rep. 2019;16:458–66. https://doi.org/10.1007/s11904-019-00471-4 .
doi: 10.1007/s11904-019-00471-4 pubmed: 31773405 pmcid: 7088640
Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis. 2004;190(1):37–45. https://doi.org/10.1086/421467 .
doi: 10.1086/421467 pubmed: 15195241
Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus–associated cancers among persons with AIDS. JNCI: Journal of the National Cancer Institute. 2009;101(16):1120-30. https://doi.org/10.1093/jnci/djp205 .
Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, Mcneel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20(12):1645–54. https://doi.org/10.1097/01.aids.0000238411.75324.59 .
doi: 10.1097/01.aids.0000238411.75324.59 pubmed: 16868446
Darwich L, Cañadas M, Videla S, Coll J, Molina-López RA, Sirera G, et al. Prevalence, clearance, and incidence of human papillomavirus type–specific infection at the anal and penile site of HIV-infected men. Sex Transm Dis. 2013;40(8):611–8. https://doi.org/10.1097/01.OLQ.0000430798.61475.08 .
doi: 10.1097/01.OLQ.0000430798.61475.08 pubmed: 23859907
de Pokomandy A, Rouleau D, Ghattas G, Vezina S, Cote P, Macleod J, et al. Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study. J Infect Dis. 2009;199(7):965–73. https://doi.org/10.1086/597207 .
doi: 10.1086/597207 pubmed: 19239366
Abraham AG, D’Souza G, Jing Y, Gange SJ, Sterling TR, Silverberg MJ, et al. Invasive cervical cancer risk among HIV-infected women: a north American multicohort collaboration prospective study. J Acquir Immune Defic Syndr. 2013;62(4):405–13. https://doi.org/10.1097/QAI.0b013e31828177d7 .
doi: 10.1097/QAI.0b013e31828177d7 pubmed: 23254153 pmcid: 3633634
Adebamowo SN, Olawande O, Famooto A, Dareng EO, Offiong R, Adebamowo CA. Persistent low-risk and high-risk human papillomavirus infections of the uterine cervix in HIV-negative and HIV-positive women. Front Public Health. 2017;5:178. https://doi.org/10.3389/fpubh.2017.00178 .
doi: 10.3389/fpubh.2017.00178 pubmed: 28785554 pmcid: 5519520
Dyson N. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;4893(243):934–7. https://doi.org/10.1126/science.2537532 .
doi: 10.1126/science.2537532
Geskus RB, González C, Torres M, Del Romero J, Viciana P, Masiá M, et al. Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men. AIDS. 2016;30(1):37–44. https://doi.org/10.1097/QAD.0000000000000874 .
doi: 10.1097/QAD.0000000000000874 pubmed: 26355673
Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO. Surgery for cervical intraepithelial neoplasia (review). Cochrane Database Syst Rev. 2013;12CD001318. https://doi.org/10.1002/14651858.CD001318 .
Pierre PL, Martin-Hirsch E, Paraskevaidis A, Bryant, Heather O, Dickinson, Sarah L, Keep. Surgery for cervical intraepithelial neoplasia (review). Cochrane Database Syst Rev. 2010;6CD001318. https://doi.org/10.1002/14651858.CD001318 .
Santesso N, Mustafa RA, Wiercioch W, Kehar R, Gandhi S, Chen Y, et al. Systematic reviews and meta-analyses of benefits and harms of cryotherapy, leep, and cold knife conization to treat cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 2016;132(3):266–71. https://doi.org/10.1016/j.ijgo.2015.07.026 .
doi: 10.1016/j.ijgo.2015.07.026 pubmed: 26643302
Follen Mitchell M, Tortolero-Luna G, Cook E, Whittaker L, Rhodes-Morris H, Silva E. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol. 1998;92(5):737–44. https://doi.org/10.1016/S0029-7844(98)00246-4 .
doi: 10.1016/S0029-7844(98)00246-4
Ferenczy A, Choukroun D, Arseneau J. Loop electrosurgical excision procedure for squamous intraepithelial lesions of the cervix: advantages and potential pitfalls. Obstet Gynecol. 1996;87(3):332–7. https://doi.org/10.1016/0029-7844(95)00453-X .
doi: 10.1016/0029-7844(95)00453-X pubmed: 8598950
Katemba C, Muzoora C, Muwanguzi E, Mwambi B, Atuhairwe C, Taremwa IM. Hematological abnormalities in HIV-antiretroviral therapy naïve clients as seen at an immune suppression syndrome clinic at Mbarara regional referral hospital, Southwestern Uganda. J Blood Med. 2018;9:105–10. https://doi.org/10.2147/JBM.S157148 .
doi: 10.2147/JBM.S157148 pubmed: 29983600 pmcid: 6027711
Antoniak S. The coagulation system in host defense. Res Pract Thromb Haemost. 2018;2(3):549–57. https://doi.org/10.1002/rth2.12109 .
doi: 10.1002/rth2.12109 pubmed: 30046760 pmcid: 6046589

Auteurs

Dewu Bi (D)

Department of Clinical Laboratory, The Fourth People's Hospital of Nanning, Nanning, Guangxi, China. dewubi@163.com.
Key Laboratory of Infectious Diseases, The Fourth People's Hospital of Nanning, Nanning, Guangxi, China. dewubi@163.com.
HIV/AIDS Clinical Treatment Center of Guangxi (Nanning), Nanning, Guangxi, China. dewubi@163.com.

Shuzhen Wei (S)

Department of Obstetrics and Gynecology, The Fourth People's Hospital of Nanning, Nanning, Guangxi, China.
HIV/AIDS Clinical Treatment Center of Guangxi (Nanning), Nanning, Guangxi, China.

Xiaolu Luo (X)

Department of Clinical Laboratory, The Fourth People's Hospital of Nanning, Nanning, Guangxi, China.
Key Laboratory of Infectious Diseases, The Fourth People's Hospital of Nanning, Nanning, Guangxi, China.
HIV/AIDS Clinical Treatment Center of Guangxi (Nanning), Nanning, Guangxi, China.

Xiaocheng Luo (X)

Department of Clinical Laboratory, The Fourth People's Hospital of Nanning, Nanning, Guangxi, China.
Key Laboratory of Infectious Diseases, The Fourth People's Hospital of Nanning, Nanning, Guangxi, China.
HIV/AIDS Clinical Treatment Center of Guangxi (Nanning), Nanning, Guangxi, China.

Xike Tang (X)

Department of Infectious Diseases, The Fourth People's Hospital of Nanning, Nanning, Guangxi, China. tangseeker@163.com.
HIV/AIDS Clinical Treatment Center of Guangxi (Nanning), Nanning, Guangxi, China. tangseeker@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH